Par Biosciences Profile
Key Indicators
- Authorised Capital ₹ 6.01 Cr
as on 30-07-2024
- Paid Up Capital ₹ 5.71 Cr
as on 30-07-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 10.89 Cr
as on 30-07-2024
- Revenue -55.73%
(FY 2023)
- Profit -12.56%
(FY 2023)
- Ebitda -64.11%
(FY 2023)
- Net Worth 10.45%
(FY 2023)
- Total Assets -17.10%
(FY 2023)
About Par Biosciences
The Corporate was formerly known as Ethics Bio Lab Private Limited. The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.01 Cr and a paid-up capital of Rs 5.71 Cr.
The company has closed loans amounting to ₹10.89 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chitti Kumar, James Papp, and Anand Raj serve as directors at the Company.
- CIN/LLPIN
U24233TN2012PTC086326
- Company No.
086326
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Par Biosciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
James Papp  | Director | 28-Jan-2021 | Current |
Chitti Kumar  | Director | 28-Jun-2017 | Current |
| Anand Raj | Director | 27-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Par Biosciences.
Par Biosciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 55.73% decrease. The company also saw a substantial fall in profitability, with a 12.56% decrease in profit. The company's net worth Soared by an impressive increase of 10.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Par Biosciences?
In 2023, Par Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Par Formulations Private LimitedActive 42 years 2 monthsChitti Kumar, James Papp and 1 more are mutual person
Par Active Technologies Private LimitedActive 11 years 1 monthChitti Kumar, James Papp and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Aug 2022 | ₹2.50 M | Satisfied |
State Bank Of India Creation Date: 19 Dec 2012 | ₹10.64 Cr | Satisfied |
How Many Employees Work at Par Biosciences?
Par Biosciences has a workforce of 39 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Par Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Par Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
